Executive Summary
HHS awarded $300,921,779 across three contracts in this period, all civilian with 0/3 defense-related, dominated by BARDA's biothreat preparedness theme in biotech R&D for antibiotics targeting drug-resistant infections and pathogens. Highest-conviction bullish signals emerge from Shionogi Inc's $119M obligation (potential $481M) and Vedanta Biosciences' $79M obligation ($70M outlayed, potential $114M), providing multi-year revenue visibility in a non-competitive, full-and-open award environment. The neutral $103M grant to DLA Troop Support adds minimal investment signal due to its low materiality and unknown revenue impact. A key risk is Shionogi's $0 outlays to date and uncertain option exercises, warranting close monitoring of funding progress. Overall, this underscores civilian HHS growth in biodefense R&D, differentiating from DOD priorities.
Tracking the trend? Catch up on the prior All HHS Contracts digest from April 07, 2026.
Investment Signals(3)
- Shionogi Inc Secures $119M HHS BARDA Contract for Biothreat Antibiotics(HIGH)▲
Shionogi Inc awarded $119,160,691 cost-plus-fixed-fee obligation (base + options $481M) by HHS BARDA for 10-year late-stage development and procurement of antibiotics against drug-resistant and biothreat pathogens, signaling multi-year biotech R&D revenue potential under full and open competition.
- Vedanta Biosciences Lands $79M HHS BARDA Award with $70M Outlayed(HIGH)▲
Vedanta Biosciences awarded $79,146,088 cost-sharing obligation ($114M potential) by HHS BARDA for biotech R&D countermeasures against antibiotic-resistant infections, with $70,681,089 already outlayed since 2020, indicating strong funding momentum through 2027 or potentially 2031.
- DLA Troop Support Receives $103M HHS Grant(LOW)▲
DLA Troop Support granted $102,615,000 from HHS, but lacks detailed revenue, competition, or sector implications, rendering it a low-materiality signal with unknown investment impact.
Risk Flags(2)
- Execution[HIGH RISK]▼
Shionogi Inc's $119M HHS BARDA contract has $0 outlays to date despite recent award, with annual revenue estimates of $11.9M highly uncertain pending funding progress.
- Execution[MEDIUM RISK]▼
Vedanta Biosciences' $79M HHS BARDA contract is cost-sharing with medium pricing risk, exposing the small business to shared financial burden amid $70M outlays.
Opportunities(2)
- ◆
Shionogi Inc's HHS BARDA contract offers upside to $481M if options exercised over 10 years for biothreat antibiotics development.
- ◆
Vedanta Biosciences' HHS BARDA award provides potential extension to 2031 and $35M options for antibiotic resistance countermeasures.
Sector Themes(1)
- ◆
Two high-materiality awards totaling $198M obligation ($595M potential) to Shionogi Inc ($119M) and Vedanta Biosciences ($79M) under NAICS 541714/PSC AN13-AZ13 for antibiotics against drug-resistant infections and biothreat pathogens, both via full and open competition.
Watch List(2)
- 👁
{"entity"=>"Shionogi Inc", "reason"=>"$119M HHS BARDA obligation with $0 outlays and $481M potential tied to 10-year biothreat antibiotics program", "trigger"=>"outlay progress from $0; option exercises; FDA marketing authorization milestones"}
- 👁
{"entity"=>"Vedanta Biosciences, Inc.", "reason"=>"$79M HHS BARDA obligation with $70M outlayed, $114M potential, and cost-sharing R&D for antibiotic resistance", "trigger"=>"remaining obligation drawdown; $35M options exercise; extension to 2031-12-31"}
Get daily alerts with 3 investment signals, 2 risk alerts, 2 opportunities and full AI analysis of all 3 filings
More from: All HHS Contracts
🇺🇸 More from United States
View all →April 20, 2026
US Pre-Market SEC Filings Roundup — April 20, 2026
US Pre-Market SEC Filings Roundup
April 20, 2026
General Federal Contracts — April 20, 2026
General Federal Contracts
April 20, 2026
High-Value Federal Grants ($5M+) — April 20, 2026
High-Value Federal Grants ($5M+)
April 20, 2026
Mega Contracts Monitor ($100M+) — April 20, 2026
Mega Contracts Monitor ($100M+)